Back to Journals » Clinical Ophthalmology » Volume 3

The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca

Authors Gumus K, Cavanagh HD

Published 7 October 2008 Volume 2009:3 Pages 57—67

DOI https://doi.org/10.2147/OPTH.S3023

Review by Single-blind

Peer reviewer comments 3


Koray Gumus1, Dwight H Cavanagh2

1Department of Ophthalmology, Erciyes University School of Medicine, Kayseri, Turkey; 2Department of Ophthalmology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA

Purpose: To review and integrate recent advances in identifying the role of inflammation in the pathogenesis of dry eye conditions and the biological rationale and practical clinical aspects of newer, antiinflammatory theories.

Methods: A comprehensive literature survey. Results and conclusion: Keratoconjunctivitis Sicca (KCS) is a multifactorial and complex disorder in which ocular surface infl ammations play a central role. Identification of specific CD4-T-Cell pathways and the recent recognition of targeting of alpha-fodrin suggest a case for novel new therapeutic aspects such as anti-CD4 monoclonal antibodies, systemic linoleic and gamma-linolenic acids, and omega-6 essential fatty acids. Replacement of tear volume with nonpreserved wetting agents and standard typical antiinflammatory corticosteroid and/or cyclosporine A continues to be central current conventional therapy for KCS.

Keywords: dry eye, keratoconjunctivitis sicca, antiinflammatory therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]